We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
+$27.5M
Cap. Flow %
3.88%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.51M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.19%
2 Healthcare 12.07%
3 Consumer Discretionary 1.47%
4 Financials 1.38%
5 Technology 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INDP icon
176
Indaptus Therapeutics
INDP
$480M
– –
-335
Closed -$164K
IONS icon
177
CALL
Ionis Pharmaceuticals
IONS
$8B
– –
-428
Closed -$1.92M
IWM icon
178
iShares Russell 2000 ETF
IWM
$76.7B
– –
-2,372
Closed -$524K
LSTA icon
179
Lisata Therapeutics
LSTA
$13.8M
– –
-32,331
Closed -$766K
PENN icon
180
PENN Entertainment
PENN
$2.39B
– –
-40,399
Closed -$4.24M
PENN icon
181
PUT
PENN Entertainment
PENN
$2.39B
– –
-731
Closed -$7.66M
PLUR icon
182
Pluri
PLUR
$14.7M
– –
-6,353
Closed -$210K
RKDA icon
183
Arcadia Biosciences
RKDA
$1.04M
– –
-1,680
Closed -$183K
RVPH
184
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-20,922
Closed -$2.4M
RVPHW
185
DELISTED
Reviva Pharmaceuticals Warrants
RVPHW
– –
-350,000
Closed -$161K
SAGE
186
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-166
Closed -$1.24M
VTSI icon
187
VirTra
VTSI
$32.8M
– –
-561,088
Closed -$3.45M
XBI icon
188
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-8,735
Closed -$1.19M
CSCI
189
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-5
Closed -$53K
RDGT
190
Ridgetech Inc
RDGT
$2.96M
– –
-1
Closed -$28K
ASXC
191
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-6,556
Closed -$2.13M
BPTH
192
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-3,596
Closed -$505K
DMK
193
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-43
Closed -$285K
NMTR
194
DELISTED
9 Meters Biopharma
NMTR
– –
-28,226
Closed -$693K
JJT
195
CALL
DELISTED
iPath Series B Bloomberg Tin Subindex Total ReturnSM ETN
JJT
– –
-14,336
Closed -$16.3M
HMCOU
196
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
– –
-67,974
Closed -$717K
MITO
197
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
– –
-301,575
Closed -$473K
PHAS
198
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-15,000
Closed -$52K
XELA
199
DELISTED
Exela Technologies, Inc. Common Stock
XELA
– –
-188
Closed -$1.64M
PTE
200
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-8,422
Closed -$234K
5 6 7
8
9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management deployed $27.5M of net new capital in Q2 2021, opening 48 new positions and adding to 50 existing holdings. Its largest new stake was Aterian: 36,083 shares worth $6.33M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, up from 76% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Vivani Medical, an estimated $4.81M trimmed.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.